Steven Seedhouse
Stock Analyst at Raymond James
(3.31)
# 1,026
Out of 4,761 analysts
163
Total ratings
43.04%
Success rate
4.24%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Steven Seedhouse
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VKTX Viking Therapeutics | Maintains: Strong Buy | $122 → $125 | $34.07 | +266.89% | 18 | Feb 6, 2025 | |
| QTTB Q32 Bio | Downgrades: Outperform | $90 → $22 | $2.57 | +756.03% | 2 | Dec 11, 2024 | |
| DNTH Dianthus Therapeutics | Maintains: Outperform | $51 → $56 | $23.67 | +136.59% | 3 | Nov 8, 2024 | |
| ETNB 89bio | Maintains: Strong Buy | $53 → $49 | $11.06 | +343.04% | 10 | Nov 8, 2024 | |
| PRQR ProQR Therapeutics | Upgrades: Strong Buy | $6 → $14 | $2.56 | +446.88% | 6 | Oct 29, 2024 | |
| KRRO Korro Bio | Initiates: Strong Buy | $153 | $26.29 | +481.97% | 1 | Oct 21, 2024 | |
| WVE Wave Life Sciences | Upgrades: Strong Buy | $13 → $22 | $11.13 | +97.66% | 2 | Oct 16, 2024 | |
| GILD Gilead Sciences | Upgrades: Outperform | $93 | $109.95 | -15.42% | 9 | Jul 8, 2024 | |
| VERA Vera Therapeutics | Maintains: Strong Buy | $57 → $68 | $28.58 | +137.93% | 3 | May 10, 2024 | |
| APLS Apellis Pharmaceuticals | Maintains: Strong Buy | $67 → $106 | $27.52 | +285.17% | 15 | Jan 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $12 → $15 | $5.06 | +196.44% | 2 | Jan 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $27 → $56 | $14.01 | +299.71% | 4 | Jan 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $78 → $64 | $52.45 | +22.02% | 18 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $19 → $18 | $0.48 | +3,544.31% | 8 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $78 → $57 | $12.17 | +368.36% | 10 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $21 → $19 | $1.83 | +938.25% | 13 | Nov 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $20 → $22 | $1.40 | +1,471.43% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $17 | $1.92 | +785.42% | 6 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $35 | $10.47 | +234.29% | 4 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $38 | $36.81 | +3.23% | 2 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $30 → $71 | $31.12 | +128.15% | 4 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $5 | $1.40 | +257.14% | 5 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $38 | $18.59 | +104.41% | 2 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $17.77 | - | 7 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.70 | - | 5 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $140.64 | - | 2 | Apr 23, 2020 |
Viking Therapeutics
Feb 6, 2025
Maintains: Strong Buy
Price Target: $122 → $125
Current: $34.07
Upside: +266.89%
Q32 Bio
Dec 11, 2024
Downgrades: Outperform
Price Target: $90 → $22
Current: $2.57
Upside: +756.03%
Dianthus Therapeutics
Nov 8, 2024
Maintains: Outperform
Price Target: $51 → $56
Current: $23.67
Upside: +136.59%
89bio
Nov 8, 2024
Maintains: Strong Buy
Price Target: $53 → $49
Current: $11.06
Upside: +343.04%
ProQR Therapeutics
Oct 29, 2024
Upgrades: Strong Buy
Price Target: $6 → $14
Current: $2.56
Upside: +446.88%
Korro Bio
Oct 21, 2024
Initiates: Strong Buy
Price Target: $153
Current: $26.29
Upside: +481.97%
Wave Life Sciences
Oct 16, 2024
Upgrades: Strong Buy
Price Target: $13 → $22
Current: $11.13
Upside: +97.66%
Gilead Sciences
Jul 8, 2024
Upgrades: Outperform
Price Target: $93
Current: $109.95
Upside: -15.42%
Vera Therapeutics
May 10, 2024
Maintains: Strong Buy
Price Target: $57 → $68
Current: $28.58
Upside: +137.93%
Apellis Pharmaceuticals
Jan 11, 2024
Maintains: Strong Buy
Price Target: $67 → $106
Current: $27.52
Upside: +285.17%
Jan 9, 2024
Maintains: Strong Buy
Price Target: $12 → $15
Current: $5.06
Upside: +196.44%
Jan 4, 2024
Maintains: Strong Buy
Price Target: $27 → $56
Current: $14.01
Upside: +299.71%
Dec 19, 2023
Maintains: Strong Buy
Price Target: $78 → $64
Current: $52.45
Upside: +22.02%
Nov 14, 2023
Maintains: Outperform
Price Target: $19 → $18
Current: $0.48
Upside: +3,544.31%
Nov 10, 2023
Maintains: Outperform
Price Target: $78 → $57
Current: $12.17
Upside: +368.36%
Nov 2, 2023
Maintains: Strong Buy
Price Target: $21 → $19
Current: $1.83
Upside: +938.25%
Aug 15, 2023
Maintains: Strong Buy
Price Target: $20 → $22
Current: $1.40
Upside: +1,471.43%
Jun 13, 2023
Upgrades: Outperform
Price Target: $17
Current: $1.92
Upside: +785.42%
May 5, 2023
Maintains: Outperform
Price Target: $33 → $35
Current: $10.47
Upside: +234.29%
May 5, 2023
Upgrades: Outperform
Price Target: $38
Current: $36.81
Upside: +3.23%
Dec 15, 2022
Maintains: Strong Buy
Price Target: $30 → $71
Current: $31.12
Upside: +128.15%
Dec 7, 2022
Maintains: Outperform
Price Target: $15 → $5
Current: $1.40
Upside: +257.14%
Nov 9, 2022
Maintains: Outperform
Price Target: $30 → $38
Current: $18.59
Upside: +104.41%
Aug 10, 2022
Downgrades: Underperform
Price Target: n/a
Current: $17.77
Upside: -
May 18, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $2.70
Upside: -
Apr 23, 2020
Downgrades: Sell
Price Target: n/a
Current: $140.64
Upside: -